| Record 13649 View: Standard | Glossary HistCite Guide |
|
Author(s): Kariko K; Ni HP; Capodici J; Lamphier M; Weissman D
Title: mRNA is an endogenous ligand for Toll-like receptor 3
Source: JOURNAL OF BIOLOGICAL CHEMISTRY 279 (13): 12542-12550
Date: 2004 MAR 26
Document Type: Journal : Article
DOI: 10.1074/jbc.M310175200
Language: English
Comment:
Address: Univ Penn, Div Neurosurg, Philadelphia, PA 19104 USA.
Univ Penn, Div Infect Dis, Philadelphia, PA 19104 USA. Eisai Res Inst, Andover, MA 01810 USA. Reprint: Kariko, K, Univ Penn, Div Neurosurg, 3610 Hamilton Walk, Philadelphia,
PA 19104 USA. E-mail: kariko@mail.med.upenn.edu
Author Keywords:
KeyWords Plus: DOUBLE-STRANDED-RNA; TRANSFECTED DENDRITIC CELLS; CYTOTOXIC T-
LYMPHOCYTES; HEAT-SHOCK PROTEINS; MHC CLASS-I; NF-KAPPA-B; CROSS-
PRESENTATION; IMMUNE-RESPONSE; TRANSCRIPTION FACTORS; ADAPTER MOLECULE
Abstract: Toll-like receptors (TLRs) are the basic signaling receptors of the innate immune system. They are activated by molecules associated with pathogens or injured host cells and tissue. TLR3 has been shown to respond to double stranded (ds) RNA, a replication intermediary for many viruses. Here we present evidence that heterologous RNA released from or associated with necrotic cells or generated by in vitro transcription also stimulates TLR3 and induces immune activation. To assess RNA-mediated TLR3 activation, human embryonic kidney 293 cells stably expressing TLR3 and containing a nuclear factor-kappaB-dependent luciferase reporter were generated. Exposing these cells to in vitro transcribed RNA resulted in a TLR3-dependent induction of luciferase activity and interleukin-8 secretion. Treatment with in vitro transcribed mRNA activated nuclear factor-kappaB via TLR3 through a process that was dose-dependent and involved tyrosine phosphorylation. Furthermore, in vitro transcribed natural or 2'-fluoro-substituted mRNA induced the expression of TLR3, interferon regulatory factor-1, tumor necrosis factor-alpha, and interleukin-1 receptor-associated kinase-M mRNA in human dendritic cells (DCs). DCs responded to mRNA treatment by expressing activation markers, and this maturation was inhibited by antagonistic TLR3-specific antibody. Endogenous RNA released from or associated with necrotic cells also stimulated DCs, leading to interferon-alpha secretion, which could be abolished by pretreatment of necrotic cells with RNase. These results demonstrate that RNA, likely through secondary structure, is a potent host-derived activator of TLR3. This finding has potential physiologic relevance because RNA escaping from damaged tissue or contained within endocytosed cells could serve as an endogenous ligand for TLR3 that induces or otherwise modulates immune responses.
Cited References: ALEXOPOULOU L, 2001, NATURE, V413, P732 ARMANT MA, 2002, GENOME BIOL BARTON GM, 2002, CURR TOP MICROBIOL, V270, P81 BASU S, 2000, INT IMMUNOL, V12, P1539 BEG AA, 2002, TRENDS IMMUNOL, V23, P509 BELZ GT, 2002, CRIT REV IMMUNOL, V22, P439 BIRAGYN A, 2002, SCIENCE, V298, P1025 DATTA SK, 2003, J IMMUNOL, V170, P4102 DENHAAN JMM, 2000, J EXP MED, V192, P1685 DOYLE SE, 2003, J IMMUNOL, V170, P3565 EILAT D, 1994, MOL IMMUNOL, V31, P1377 GINSBERG SD, 1998, ACTA NEUROPATHOL, V96, P487 GINSBERG SD, 1999, ANN NEUROL, V45, P174 GORDON S, 2002, CELL, V111, P927 GRENTZMANN G, 1998, RNA, V4, P479 GUILLOT L, 2002, J IMMUNOL, V168, P5989 HEISER A, 2001, J IMMUNOL, V166, P2953 HEISER A, 2002, J CLIN INVEST, V109, P409 HORNG T, 2001, NAT IMMUNOL, V2, P835 JIANG ZF, 2003, J BIOL CHEM, V278, P10952, DOI 10.1074/jbc.M212112200 JOHNSON GB, 2002, J IMMUNOL, V168, P5233 KADOWAKI N, 2001, J EXP MED, V194, P863 KARIKO K, 1998, BBA-BIOMEMBRANES, V1369, P320 KIRSCHNING CJ, 2002, CURR TOP MICROBIOL, V270, P121 KOBAYASHI K, 2002, CELL, V110, P191 KROGER A, 2002, J INTERF CYTOK RES, V22, P5 LARSSON M, 2003, CURR TOP MICROBIOL, V276, P261 LEADBETTER EA, 2002, NATURE, V416, P603 MARCINKIEWICZ M, 2002, J NEUROPATH EXP NEUR, V61, P815 MATSUMOTO M, 2002, BIOCHEM BIOPH RES CO, V293, P1364 MATSUYAMA T, 1993, CELL, V75, P83 MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991 MATZINGER P, 2002, ANN NY ACAD SCI, V961, P341 MAURER T, 2002, EUR J IMMUNOL, V32, P2356 MIETTINEN M, 2001, GENES IMMUN, V2, P349 MUZIO M, 2000, J IMMUNOL, V164, P5998 NAIR SK, 1998, NAT BIOTECHNOL, V16, P364 NAIR SK, 2000, NAT MED, V6, P1011 NAIR SK, 2002, ANN SURG, V235, P540 NI HP, 2002, J BIOL CHEM, V277, P12689 OSHIUMI H, 2003, NAT IMMUNOL, V4, P161, DOI 10.1038/ni886 PLEVY SE, 1997, MOL CELL BIOL, V17, P4572 ROSENBERG HF, 2001, J LEUKOCYTE BIOL, V70, P691 SARKAR SN, 2003, J BIOL CHEM, V278, P4393, DOI 10.1074/jbc.C200655200 SATO M, 2001, CYTOKINE GROWTH F R, V12, P133 SAUNDERS LR, 2003, FASEB J, V17, P961 SHINOBU N, 2002, FEBS LETT, V517, P251 SMILEY ST, 2001, J IMMUNOL, V167, P2887 SMITH CL, 2000, MOL ENDOCRINOL, V14, P956 TANIGUCHI T, 2001, ANNU REV IMMUNOL, V19, P623 TERMEER C, 2002, J EXP MED, V195, P99 TOSHCHAKOV V, 2002, NAT IMMUNOL, V3, P392 VABULAS RM, 2002, CURR TOP MICROBIOL, V270, P169 VISINTIN A, 2001, J IMMUNOL, V166, P249 WEINMANN AS, 2001, NAT IMMUNOL, V2, P51 WEISSMAN D, 2000, J IMMUNOL, V165, P4710 WERLING D, 2003, VET IMMUNOL IMMUNOP, V91, P1 WILLIAMS BR, 2001, SCI STKE YAMAMOTO M, 2002, J IMMUNOL, V169, P6668 YANG H, 2000, J BIOL CHEM, V275, P20861 YASUTOMO K, 2001, NAT GENET, V28, P313 ZINKERNAGEL RM, 2002, EUR J IMMUNOL, V32, P2385 ZUKER M, 1981, NUCLEIC ACIDS RES, V9, P133 ZUKER M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595 |